124 related articles for article (PubMed ID: 26542740)
1. Toward illness phase-specific pharmacotherapy for schizophrenia.
Krystal JH; Anticevic A
Biol Psychiatry; 2015 Dec; 78(11):738-40. PubMed ID: 26542740
[No Abstract] [Full Text] [Related]
2. Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2/3 receptor agonist pomaglumetad methionil in schizophrenia.
Kinon BJ; Millen BA; Zhang L; McKinzie DL
Biol Psychiatry; 2015 Dec; 78(11):754-62. PubMed ID: 25890643
[TBL] [Abstract][Full Text] [Related]
3. Neither typical nor atypical: LY404039 provides proof of concept that selective targeting of mGluR2/3 receptors is a valid mechanism for obtaining antipsychotic efficacy.
Lebois EP
Curr Top Med Chem; 2008; 8(16):1480-1. PubMed ID: 19006848
[No Abstract] [Full Text] [Related]
4. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.
Patil ST; Zhang L; Martenyi F; Lowe SL; Jackson KA; Andreev BV; Avedisova AS; Bardenstein LM; Gurovich IY; Morozova MA; Mosolov SN; Neznanov NG; Reznik AM; Smulevich AB; Tochilov VA; Johnson BG; Monn JA; Schoepp DD
Nat Med; 2007 Sep; 13(9):1102-7. PubMed ID: 17767166
[TBL] [Abstract][Full Text] [Related]
5. LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia.
Mezler M; Geneste H; Gault L; Marek GJ
Curr Opin Investig Drugs; 2010 Jul; 11(7):833-45. PubMed ID: 20571979
[TBL] [Abstract][Full Text] [Related]
6. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039).
Fell MJ; Svensson KA; Johnson BG; Schoepp DD
J Pharmacol Exp Ther; 2008 Jul; 326(1):209-17. PubMed ID: 18424625
[TBL] [Abstract][Full Text] [Related]
7. An agonist at glutamate and dopamine D2 receptors, LY404039.
Seeman P
Neuropharmacology; 2013 Mar; 66():87-8. PubMed ID: 22884896
[No Abstract] [Full Text] [Related]
8. NN-414. Novo Nordisk.
Choi JK
Curr Opin Investig Drugs; 2003 Apr; 4(4):455-8. PubMed ID: 12808887
[TBL] [Abstract][Full Text] [Related]
9. Glutamate agonists for schizophrenia stimulate dopamine D2High receptors.
Seeman P
Schizophr Res; 2008 Feb; 99(1-3):373-4. PubMed ID: 18077139
[No Abstract] [Full Text] [Related]
10. A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity.
Galici R; Echemendia NG; Rodriguez AL; Conn PJ
J Pharmacol Exp Ther; 2005 Dec; 315(3):1181-7. PubMed ID: 16123306
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identification of potent, selective, and orally bioavailable agonists for mGlu2/3 receptors.
Monn JA; Massey SM; Valli MJ; Henry SS; Stephenson GA; Bures M; Hérin M; Catlow J; Giera D; Wright RA; Johnson BG; Andis SL; Kingston A; Schoepp DD
J Med Chem; 2007 Jan; 50(2):233-40. PubMed ID: 17228865
[TBL] [Abstract][Full Text] [Related]
12. Metabotropic glutamate receptor agonists for schizophrenia.
Harrison PJ
Br J Psychiatry; 2008 Feb; 192(2):86-7. PubMed ID: 18245019
[TBL] [Abstract][Full Text] [Related]
13. The reversal of cognitive, but not negative or positive symptoms of schizophrenia, by the mGlu₂/₃ receptor agonist, LY379268, is 5-HT₁A dependent.
Wierońska JM; Sławińska A; Stachowicz K; Łasoń-Tyburkiewicz M; Gruca P; Papp M; Pilc A
Behav Brain Res; 2013 Nov; 256():298-304. PubMed ID: 23948211
[TBL] [Abstract][Full Text] [Related]
14. Relative contributions of presystemic and systemic peptidases to oral exposure of a novel metabotropic glutamate 2/3 receptor agonist (LY404039) after oral administration of prodrug pomaglumetad methionil (LY2140023).
Annes WF; Long A; Witcher JW; Ayan-Oshodi MA; Knadler MP; Zhang W; Mitchell MI; Cornelissen K; Hall SD
J Pharm Sci; 2015 Jan; 104(1):207-14. PubMed ID: 25382826
[TBL] [Abstract][Full Text] [Related]
15. Metabotropic glutamate receptors as targets for novel antipsychotic treatments.
Gray LJ; Hannan AJ; Zhang X
Curr Pharm Biotechnol; 2012 Jun; 13(8):1522-34. PubMed ID: 22283756
[TBL] [Abstract][Full Text] [Related]
16. Levels of the Rab GDP dissociation inhibitor (GDI) are altered in the prenatal restrain stress mouse model of schizophrenia and are differentially regulated by the mGlu2/3 receptor agonists, LY379268 and LY354740.
Orlando R; Borro M; Motolese M; Molinaro G; Scaccianoce S; Caruso A; di Nuzzo L; Caraci F; Matrisciano F; Pittaluga A; Mairesse J; Simmaco M; Nisticò R; Monn JA; Nicoletti F
Neuropharmacology; 2014 Nov; 86():133-44. PubMed ID: 25063582
[TBL] [Abstract][Full Text] [Related]
17. [The use of mGlu2/3 receptors as a new approach to treat schizophrenia: results of a randomized double-blind trial].
Mosolov SN; Smulevich AB; Neznanov NG; Tochilov VA; Andreev BV; Avedisova AS; Bardenshteĭn LM; Gurovich IIa; Reznik AM; Zharkova NB; Martenyi F
Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(7):16-23. PubMed ID: 20639852
[TBL] [Abstract][Full Text] [Related]
18. Comment on: "Effects of a novel mGlu(2/3) receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid" (Lowe S, Dean R, Ackermann B, Jackson K, Natanegara F, Anderson S, Eckstein J, Yuen E, Ayan-Oshodi M, Ho M, McKinzie D, Perry K, Svensson K, Psychopharmacology, 2012).
Seeman P
Psychopharmacology (Berl); 2012 May; 221(2):355-6; author reply 357-8. PubMed ID: 22411429
[No Abstract] [Full Text] [Related]
19. Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).
Rorick-Kehn LM; Johnson BG; Burkey JL; Wright RA; Calligaro DO; Marek GJ; Nisenbaum ES; Catlow JT; Kingston AE; Giera DD; Herin MF; Monn JA; McKinzie DL; Schoepp DD
J Pharmacol Exp Ther; 2007 Apr; 321(1):308-17. PubMed ID: 17204749
[TBL] [Abstract][Full Text] [Related]
20. Group II metabotropic glutamate receptor agonists as a potential drug for schizophrenia.
Chaki S
Eur J Pharmacol; 2010 Aug; 639(1-3):59-66. PubMed ID: 20371240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
